Puma Biotechnology Inc Revenue Growth Rates (PBYI), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Puma Biotechnology Inc   (NASDAQ: PBYI)
 

PBYI's Revenue Growth by Quarter and Year

Puma Biotechnology Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PBYI Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 56.50
1st Quarter March 44.81
FY 101.31

PBYIs Annual Revenue
Puma Biotechnology Inc 's Revenue in the fiscal year 2025 $ 228.37 millions
Puma Biotechnology Inc 's Revenue in the fiscal year 2024 $ 230.47 millions
Puma Biotechnology Inc 's Revenue in the fiscal year 2023 $ 235.64 millions
Puma Biotechnology Inc 's Revenue in the fiscal year 2022 $ 228.03 millions
Puma Biotechnology Inc 's Revenue in the fiscal year 2021 $ 253.16 millions




PBYI Revenue second quarter 2026 Y/Y Growth Comment
Puma Biotechnology Inc achieved in the second quarter 2026, above Company average Revenue improvement of 7.75% year on year, to $ 56.50 millions.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 120 other companies have achieved higher Revenue growth. While Puma Biotechnology Inc ' s Revenue increase of 7.75% ranks overall at the positon no. 2512 in the second quarter 2026.


PBYI Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 27.71 % -18.15 % 9.9 %
3rd Quarter September - -32.36 % 43.51 % -1.72 %
2nd Quarter June 7.75 % 11.38 % -13.73 % -8.32 %
1st Quarter March -2.61 % 5.12 % -17.07 % 15.39 %
FY   - -0.91 % -2.2 % -

Financial Statements
Puma Biotechnology Inc 's second quarter 2026 Revenue $ 56.50 millions PBYI's Income Statement
Puma Biotechnology Inc 's second quarter 2025 Revenue $ 52.44 millions Quarterly PBYI's Income Statement


PBYI Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 38.49 % -26.65 % 28.62 %
3rd Quarter September - 3.89 % 71.07 % 2.84 %
2nd Quarter June 26.09 % 13.98 % 7.56 % 3.39 %
1st Quarter March -40.61 % -22.12 % -39.36 % -19.64 %
FY (Year on Year)   - -0.91 % -2.2 % -


Back to PBYI Growth rate Comparisons >> Back to PBYI Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #121
Healthcare Sector #366
Overall #2512

Revenue Y/Y Growth Statistics
High Average Low
97.76 % 2.88 % -26.22 %
(Jun 30 2019)   (Mar 31 2022)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #121
Healthcare Sector #366
Overall #2512
Revenue Y/Y Growth Statistics
High Average Low
97.76 % 2.88 % -26.22 %
(Jun 30 2019)   (Mar 31 2022)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Puma Biotechnology Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
255.57 % 17.14 % -45.62 %
(Dec 31 2017)  


PBYI's II. Quarter Q/Q Revenue Comment
Puma Biotechnology Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 26.09%, to $ 56.50 millions, from $44.81 millions in the first quarter.
PBYI is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 43 other companies have achieved higher Revenue quarter on quarter growth. While Puma Biotechnology Inc 's Revenue growth quarter on quarter, overall rank is 410.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #44
Healthcare Sector #92
Overall #410
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #44
Healthcare Sector #92
Overall #410
Revenue Q/Q Growth Statistics
High Average Low
255.57 % 17.14 % -45.62 %
(Dec 31 2017)  


PBYI's II. Quarter Q/Q Revenue Comment
Puma Biotechnology Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 26.09%, to $ 56.50 millions, from $44.81 millions in the first quarter.
PBYI is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 43 other companies have achieved higher Revenue quarter on quarter growth. While Puma Biotechnology Inc 's Revenue growth quarter on quarter, overall rank is 410.


Puma Biotechnology Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 231.24 $ 227.18 $ 228.37 $ 212.00 $ 238.06
Y / Y Revenue Growth (TTM) -2.86 % -2.38 % -0.91 % -12.96 % 8.63 %
Year on Year Revenue Growth Overall Ranking # 2318 # 2198 # 1671 # 2179 # 2222
Seqeuential Revenue Change (TTM) 1.79 % -0.52 % 7.72 % -10.95 % 2.3 %
Seq. Revenue Growth (TTM) Overall Ranking # 2512 # 2379 # 1617 # 924 # 1828


Cumulative Revenue growth Comment
Puma Biotechnology Inc 's cumulative 12 months Revenue continue to decrease, but on the faster rate at -2.86% year on year, at Jun 30 2026 compare to the -2.38% decrease at Mar 31 2026. If the Puma Biotechnology Inc 's fiscal year would end at Jun 30 2026, annual Revenue would be $231 millions.

In the Healthcare sector 337 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2198 to 2318.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 338
Overall # 2318

Revenue TTM Y/Y Growth Statistics
High Average Low
97.76 %
 2.88 %
-26.22 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 366
S&P 500 # 2512
Cumulative Revenue growth Comment
Puma Biotechnology Inc 's cumulative 12 months Revenue continue to decrease, but on the faster rate at -2.86% year on year, at Jun 30 2026 compare to the -2.38% decrease at Mar 31 2026. If the Puma Biotechnology Inc 's fiscal year would end at Jun 30 2026, annual Revenue would be $231 millions.

In the Healthcare sector 337 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2198 to 2318.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 338
Overall # 2318

Revenue TTM Y/Y Growth Statistics
High Average Low
97.76 %
2.88 %
-26.22 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 366
S&P 500 # 2512




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PBYI's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Atricure Inc 13.38%$ 13.376 millions
Dexcom Inc 13.11%$ 13.105 millions
Sanara Medtech Inc 13.03%$ 13.028 millions
Bausch Health Companies Inc 12.73%$ 12.727 millions
Vertex Pharmaceuticals Inc12.45%$ 12.453 millions
Genedx Holdings Corp 12.30%$ 12.304 millions
Profound Medical Corp 12.30%$ 12.302 millions
Xenetic Biosciences Inc 11.99%$ 11.986 millions
Biolife Solutions Inc 11.98%$ 11.978 millions
Repligen Corp11.93%$ 11.933 millions
Medline Inc 11.60%$ 11.603 millions
Earth Science Tech Inc 11.56%$ 11.556 millions
Immucell Corporation11.50%$ 11.501 millions
Harrow Inc 11.26%$ 11.256 millions
Rapid Micro Biosystems Inc 10.91%$ 10.906 millions
Livanova Plc10.80%$ 10.797 millions
Cerus Corporation10.52%$ 10.517 millions
Interpace Biosciences Inc 10.33%$ 10.331 millions
Warby Parker Inc 10.25%$ 10.253 millions
Neuronetics Inc 10.25%$ 10.249 millions
Elanco Animal Health Incorporated10.23%$ 10.234 millions
Quest Diagnostics Inc10.21%$ 10.214 millions
Gilead Sciences Inc 10.18%$ 10.181 millions
Lifeloc Technologies Inc 10.16%$ 10.163 millions
Abbvie Inc 10.16%$ 10.160 millions
Concentra Group Holdings Parent Inc 10.03%$ 10.030 millions
Lemaitre Vascular Inc 10.02%$ 10.017 millions
Amneal Pharmaceuticals Inc 9.93%$ 9.934 millions
Merit Medical Systems Inc9.79%$ 9.792 millions
Idexx Laboratories Inc9.73%$ 9.728 millions


About Puma Biotechnology Inc Revenue Growth Rates (PBYI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Puma Biotechnology Inc (CIK 1401667).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001437749-26-026311
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Puma Biotechnology Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.